References
- 1. Bruijnincx PC, Sadler PJ. New trends for metal complexes with anticancer activity. Curr Opin Chem Biol 2008; 12(2): 197-206.
- 2. van Rijt SH, Sadler PJ. Current applications and future potential for bioinorganic chemistry in the development of anticancer drugs. Drug Discov Today 2009; 14(23-24): 1089-97, DOI: 10.1016/j.drudis.2009.09.003.
- 3. Oun R, Wheate NJ. Platinum Anticancer Drugs. In: Kretsinger RH, Uversky VN, Permiyakov EA: Encyclopedia of Metalloproteins. New York, Heidelberg, Dordrecht, London: Springer 2013: pp.1710-14.
- 4. Cepeda V, Fuertes MA, Castilla J, Alonso C, Quevedo C, Peres JM. Biochemical Mechanisms of Cisplatin Cytotoxicity. Anticancer Agents Med Chem 2007; 7(1): 3-18.
- 5. Weijl NI, Hopman GD, Wipkink-Bakker A, Lentjes EG, Berger HM, Cleton FJ, Osanto S. Cisplatin combination chemotherapy induces a fall in plasma antioxidants of cancer patients. Ann Oncol 1998; 9(12): 1331–7.
- 6. Jung Y, Lippard SJ. Direct cellular responses to platinum induced DNA damage. Chem Rev 2007; 107: 1387-1407.
- 7. Rabik CA, Dolan ME. Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev 2007; 33(1): 9–23.
- 8. van Zutphen S, Reedijk J. Targeting platinum anti-tumour drugs: overview of strategies employed to reduce systemic toxicity. Coord Chem Rev 2005; 249: 2845-53.
- 9. Barry NP, Sadler PJ. Exploration of the medical periodic table: towards new targets. Chem Commun (Camb) 2013; 49: 5106-31.
- 10. Pai V, Nahata M. Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention. Drug Saf 2000; 22(4): 263–302.
- 11. Patanè S. Cardiotoxicity: cisplatin and long-term cancer survivors. Int J Cardiol 2014; 175(1): 201–2.
- 12. Al-Majed AA, Sayed-Ahmed MM, Al-Yahya AA, Aleisa AM, Al-Rejaie SS, Al-Shabanah OA. Propionyl-L-carnitine prevents the progression of cisplatin-induced cardiomyopathy in a carnitine-depleted rat model. Pharmacol Res 2006; 53(3): 278–86.
- 13. Meinardi MT, Gietema JA, van der Graaf WT, van Veldhuisen DJ, Runne MA, Sluiter WJ et al. Cardiovascular morbidity in long term survivors of metastatic testicular cancer. J Clin Oncol 2000; 18: 1725 32.
- 14. Kucharz J, Michalowska-Kaczmarczyk A, Zygulska A, Wojtak J et al. Bradycardia as a rare symptom of cisplatin cardiotoxicity: a case report. Oncol Lett 2016; 11(3): 2297-99.
- 15. Albini A, Pennesi G, Donatelli F, Cammarota R, De Flora S, Noonan DM. Cardiotoxicity of anticancer drugs: The need for Cardio-Oncology and Cardio-Oncological Prevention. J Natl Cancer Inst 2010; 102:14–25.
- 16. Minotti G, Salvatorelli E, Menna P. Pharmacological foundations of cardio-oncology. J Pharmacol Exp Ther 2010; 334: 2–8.
- 17. Chirino YI, Pedraza-Chaverri J. Role of oxidative and nitrosative stress in cisplatin-induced nephrotoxicity. Exp Toxicol Pathol 2009; 61(3): 223-42.
- 18. Hussein A, Ahmed AA, Shouman SA, Sharawy S. Ameliorating effect of DL-a-lipoic acid against cisplatin-induced nephrotoxicity and cardiotoxicity in experimental animals. Drug Discov Ther 2012; 6(3): 147–56.
- 19. Auclair C, Voisin E. Nitroblue tetrazolium reduction. In: Greenvvald RA (Ed.): Handbook of methods for oxygen radical research. CRC Press, Boca Raton 1985; 123–32.
- 20. Pick E, Keisari Y. A simple colorimetric method for the measurement of hydrogen peroxide produced by cells in culture. J Immunol Methods 1980; 38: 161–70.
- 21. Green LC, Wagner DA, Glogowski J, Skipper PL, Wishnok JS, Tannenbaum SR. Analysis of nitrate, nitrite and [15N] nitrate in biological fluids. Anal Biochem 1982; 126(1): 131–8.
- 22. Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 1979; 95(2): 351–8.
- 23. Galanski M, Keppler BK. Synthesis and characterization of new ethylendiamine platinum (IV) complexes containing lipophilic carboxylate ligands. Metal Based Drugs 1995; 2: 57-63.
- 24. Ma H, Jones KR, Guo R, Xu P, Shen Y, Ren J. Cisplatin compromises myocardial contractile function and mitochondrial ultrastructure: role of endoplasmic reticulum stress. Clin Exp Pharmacol Physiol 2010; 37: 460-5.
- 25. Ferroni P, Della-Morte D, Palmirotta R, McClendon M, Testa G, Abete P et al. Platinum-based compounds and risk for cardiovascular toxicity in elderly: role of the antioxidants in chemoprevention. Rejuvenation Res 2011; 14: 293-308.
- 26. El-Awady ES, Moustafa YM, Abo-Elmatty DM, Radwan A. Cisplatin-induced cardiotoxicity: mechanisms and cardioprotective strategies. Eur J Pharmacol 2011; 650: 335–41.
- 27. Sawyer DB, Fukazawa R, Arstall MA, Kelly RA. Daunorubicin-induced apoptosis in rat cardiac myocytes is inhibited by dexrazoxane. Circ Res 1999; 84: 257-65.
- 28. Park MS, De Leon M, Devarajan P. Cisplatin induces apoptosis in LLC-PK1 cells via activation of mitochondrial pathways. J Am Soc Nephrol 2002; 13: 858-65.
- 29. Devarajan P, Savoca M, Castaneda MP, Park MS, Esteban-Cruciani N, Kalinec G et al. Cisplatin-induced apoptosis in auditory cells: role of death receptor and mitochondrial pathways. Heart Res 2002; 17: 45-54.
- 30. Varga ZV, Ferdinandy P, Liaudet L, Pacher P. Drug-induced mitochondrial dysfunction and cardiotoxicity. Am J Physiol Heart Circ Physiol 2015; 309(9): H1453-67.
- 31. Martins NM, Santos NA, Curti C, Bianchi ML, Santos AC. Cisplatin induces mitochondrial oxidative stress with resultant energetic metabolism impairment, membrane rigidification and apoptosis in rat liver. J Appl Toxicol 2008; 28(3): 337-44.
- 32. Yuce A, Atessahin A, Ceribasi AO, Aksakal M. Ellagic acid prevents cisplatin-induced oxidative stress in liver and heart tissue of rats. Basic Clin Pharmacol Toxicol 2007; 101(5): 345-9.
- 33. Halliwell B. Reactive species and antioxidants. Redox biology is a fundamental theme of aerobic life. Plant Physiol 2006; 141: 312-22.
- 34. Nakhaee A, Bokaeian M, Noori S, Mahboob T. Antioxidant effect of carnosine pretreatment on cisplatin-induced renal oxidative stress in rats. Indian J Clin Biochem 2010; 25: 86–91.
- 35. Jakupec MA, Galanski M, Keppler BK. Tumour-inhibiting platinum complexes-state of the art and future perspectives. Rev Physiol Biochem Pharmacol 2003; 146: 1-53.
- 36. Baek SM, Kwon CH, Kim JH, Woo Js, Jung JS, Kim YK. Differential roles of hydrogen peroxide and hydroxyl radical in cisplatin-induced cell death in renal proximal tubular epithelial cells. J Lab Clin Med 2003; 142(3): 178-86.
- 37. Demkow U, Stelmaszczyk-Emmel A. Cardiotoxicity of cisplatin-based chemotherapy in advanced non-small cell lung cancer patients. Respir Physiol Neurobiol 2013; 187:64-7.
- 38. Crohns M, Liippo K, Erhola M, Kankaanranta H, Moilanen E, Alho H et al. Concurrent decline of several antioxidants and markers of oxidative stress during combination chemotherapy for small cell lung cancer. Clinical Biochemistry 2009; 42: 1236–45.
- 39. Zhou J, Zhu Q, Yao H. Chemotherapy of non-small-cell lung cancer (NSCLC) and changes in serum sAPO-1/Fas and nitric oxide (NO) levels. Chin J Onc 2000; 22: 225–7.
- 40. Colakogullari M, Ulukaya E, Yilmaztepe A, Ocakoglu G, Yilmaz M, Karadag M et al. Higher serum nitrate levels are associated with poor survival in lung cancer patients. Clinical Biochemistry 2006; 39: 898–903.
- 41. Conklin KA, Nicolson GL. Molecular replacement in cancer therapy: reversing cancer metabolic and mitochondrial dysfunction, fatigue and the adverse effects of cancer therapy. Curr Cancer Ther Rev 2008; 4: 66-76.
- 42. Deavall DG, Martin EA, Horner JM, Roberts R. Drug-induced oxidative stress and toxicity. J Toxicol. 2012; 645460 DOI: 10.1155/2012/645460.
- 43. Dasari S, Tchounwou PB. Cisplatin in cancer therapy: Molecular mechanisms of action. Eur J Pharmacol 2014; 740: 364-78.